Loading JYL Briefings...
JYL Briefings 2026
MAY
W22 May 25 - May 31 The week's signal: computational evidence moved from supplement to pathway-grade. A protein-biology world model shipped under MIT license with lab-confirmed binders, FDA put organoids, microphysiological systems, and... Weekly Brief · 17 min · Life Sciences / Regulatory Open W21 May 18 - May 24 Computational drug design crossed a generalization threshold, agentic AI absorbed thirty life-science databases into one query surface, the UK proposed collapsing trial and marketing authorization into a single instru... Weekly Brief · 18 min · Life Sciences / Regulatory Open W20 May 11 - May 17 The inspection clock compressed, the UK device map redrew, a frontier multimodal diagnostic AI cleared peer review, the first BCL-2 inhibitor landed in mantle cell lymphoma on a triple-expedited stack, the 30-year FDA... Weekly Brief · 24 min · Life Sciences / Regulatory Open W19 May 4 - May 10 A new clinical modality cleared, the regulator's review stack went AI-augmented, the post-approval coverage gap collapsed, a top-5 pharma signed itself wall-to-wall to a frontier model vendor, and a state medical boar... Weekly Brief · 18 min · Life Sciences / Regulatory Open APR
W18 Apr 27 - May 3 The trial-data pipeline, the regulator's own org chart, and the implementation layer all moved this week — FDA collapsed batch-mode trial submission into continuous streaming with two named sponsors live, MHRA hired i... Weekly Brief · 16 min · Life Sciences / Regulatory Open W17 Apr 20 - Apr 26 The federal regulatory stack moved from talking about AI and access to enforcing them — pricing the cost of overreliance, compressing the timeline from authorization to coverage, and re-drawing the line between AI-ass... Weekly Brief · 22 min · Life Sciences / Regulatory Open W16 Apr 13 - Apr 19 The regulatory ceiling hardened on both sides of the Atlantic this week — and three frontier-AI vendors (Anthropic, OpenAI, AWS) each shipped their own biopharma-specific move in the same 48-hour window. The vendor-ev... Weekly Brief · 24 min · Life Sciences / Regulatory Open W15 Apr 6 - Apr 12 Five distinct regulatory and evidence surfaces shifted this week. Two are official pathway or regulatory actions (MHRA olezarsen approval and aligned pathway; FDA DHT RFI). Three are evidence-surface shifts (clinical-... Weekly Brief · 13 min · Life Sciences / Regulatory Open MAR
W14 Mar 30 - Apr 5 This week had one confirmed regulatory action (UK MHRA clinical trial timing reform), one strong peer-reviewed science cluster (drug delivery papers), and two preprint-stage signals (DFNZ opioid pharmacology and Speci... Weekly Brief · 12 min · Life Sciences / Regulatory Open W13 Mar 23 - Mar 29 Japan broke new ground by conditionally approving the world's first two iPSC-derived cell therapies, while the FDA approved the first gene therapy for LAD-I, the MHRA overhauled its approval timeline, and Lilly placed... Weekly Brief · 11 min · Life Sciences / Regulatory Open W12 Mar 16 - Mar 22 The FDA approved two first-in-class drugs in the same week — an oral IL-23 blocker for psoriasis and the first treatment for PBC-related itch — while two Nature papers converged on multi-organ axes for neurodegenerati... Weekly Brief · 8 min · Life Sciences / Regulatory Open W11 Mar 9 - Mar 15 The week's biggest signal is that AI-discovered drugs are generating real clinical data — and the regulatory system is simultaneously inventing new approval pathways to handle what comes next. Weekly Brief · 8 min · Life Sciences / Regulatory Open W10 Mar 2 - Mar 8 A Science paper reported a CD70-HIT CAR-T signal against "hidden" antigen expression that conventional assays miss, DeepMind's diagnostic AI posted 90% accuracy in a real primary care clinic, the FDA announced it will... Weekly Brief · 12 min · Life Sciences / Regulatory Open FEB
W09 Feb 23 - Mar 1 February's regulatory baseline still defined the March window: QMSR compliance had just gone mandatory, FDA had already cleared the first AI tool that simultaneously detects and characterizes lung cancer on CT, and gu... Weekly Brief · 12 min · Life Sciences / Regulatory Open W08 Feb 16 - Feb 22 The February 16-22 window captured the week the FDA's quality system changed and the major AI labs raced to add medical features without regulatory infrastructure — QMSR went live on February 2, the cybersecurity prem... Weekly Brief · 12 min · Life Sciences / Regulatory Open W07 Feb 9 - Feb 15 The February 9-15 window arrived one week after the most consequential device quality regulatory shift in three decades — QMSR's February 2 effective date — while the EMA-FDA joint AI principles published in January m... Weekly Brief · 12 min · Life Sciences / Regulatory Open W06 Feb 2 - Feb 8 The most significant regulatory infrastructure shift in 30 years hit enforcement this week: FDA's QMSR replaced the 1996 QSR on February 2, and FDA issued QMSR-aligned cybersecurity premarket guidance the very next da... Weekly Brief · 11 min · Life Sciences / Regulatory Open JAN
W05 Jan 26 - Feb 1 The late-January to early-February regulatory stack rewired itself across a window boundary: QMSR took effect Feb 2 replacing the inspection paradigm, the FDA deregulated swaths of CDS and wearable oversight, launched... Weekly Brief · 11 min · Life Sciences / Regulatory Open W04 Jan 19 - Jan 25 The FDA executed a coordinated January package across adjacent windows — W01 (Jan 6: CDS and General Wellness final guidances), W01 (Jan 14: FDA x EMA joint AI-in-drug-development principles), and now (W04: cleared de... Weekly Brief · 12 min · Life Sciences / Regulatory Open W03 Jan 12 - Jan 18 FDA deregulated two categories of AI health software simultaneously while opening a new limited review pathway for chronic disease digital health — the largest shift in the digital health regulatory posture in recent... Weekly Brief · 9 min · Life Sciences / Regulatory Open W02 Jan 5 - Jan 11 FDA opened 2026 with its largest digital health deregulation in a decade — revising CDS and general wellness guidance to remove premarket review from single-recommendation tools and non-invasive wearable monitoring —... Weekly Brief · 11 min · Life Sciences / Regulatory Open DEC
W01 Dec 29 - Jan 4 The opening January window of 2026 produced the most significant regulatory signal in recent memory: FDA and EMA issued their first joint AI principles for drug development, creating a transatlantic compliance baselin... Weekly Brief · 10 min · Life Sciences / Regulatory Open Weekly Quarterly